Clinical Trial

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5 months.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-12.
Trial Details
NCT Number NCT07476001
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 12 participants
Start Date 2026-03-03
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-15